Imatinib Drug Market
Imatinib Drug Market Size, Share & Trends Analysis Report, by Drug Form (Tablet and Capsules), by Application (Blood Cancer (Leukemia and Other Blood Cancers), Gastrointestinal Stromal Tumors (GIST), Skin Tumors (Dermatofibrosarcoma Protuberans), and Other Tumors) and Forecast Period, 2020-2026 Update Available - Forecast 2024-2030
The global imatinib drug market is estimated to grow at a CAGR of around 4% during the forecast period. The major factors contributing to the growth of the market include the rising prevalence of cancer and an increase in awareness programs towards cancer by government and private organizations. Imatinib is a chemotherapy drug that used to slow down or stopping the growth of the cancer cells. This medication is used for the treatment of certain types of cancer including, acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic syndrome. Imatinib drug helps in improving blood count which makes it highly effective and attracting the target patients for the adoption of this drug leading to the significant growth of the imatinib drug market.
Segmentation
The global imatinib drug market is segmented based on drug form, and application. Based on drug form, the market is classified into tablets and capsules. Based on application the market is classified into blood cancer (leukemia and other blood cancers), gastrointestinal stromal tumors (GIST), skin tumors (dermatofibrosarcoma protuberans), and other tumors such as systemic mastocytosis. Blood cancer segment is expected to hold the major market share owing to increasing demand for imatinib for the treatment of different types of leukemia cancers such as Acute myeloid (or myelogenous) leukemia (AML), Chronic myeloid (or myelogenous) leukemia (CML), Acute lymphocytic (or lymphoblastic) leukemia (ALL), and Chronic lymphocytic leukemia (CLL).
Regional Outlook
Geographically, the global imatinib drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a major share in the market owing to the growing concern towards healthcare. According to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are diagnosed in the US whereas around 600,000 died of cancer. The high prevalence of cancer is augmenting the growth of the imatinib drug market as leukemia is one of the most common cancers in the US. The presence of major companies in the region is propelling the growth of imatinib drug. These companies are significantly focusing on marketing their products across the globe and gain a competitive advantage.
Global Imatinib Drug Market Growth, by Region 2020-2026
The Asia-Pacific has witnessed potential growth in the market
Asia-Pacific is estimated to witness significant growth in the market owing to the significant prevalence of the geriatric population and growing awareness towards cancer is primarily encouraging the market growth in the region. Increasing healthcare expenditure and the increasing number of multi-specialty hospitals and oncology clinics is further strengthening the market growth in the region. Moreover, the major companies are expanding their presence in this region, which in turn, will likely contribute to the significant growth of the imatinib drug market in the region.
Competitive Landscape
The major companies providing imatinib drugs include Dr. Reddy’s Laboratories, Ltd, Lupin, Ltd., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industry, Ltd. The introduction of generic drugs by most of these players is expected to impact the market value. For instance, in July 2019, Lupin Ltd. announced the launch of Imatinib Mesylate tablets, 100mg (base) and 400 mg (base). Lupin alliance partner Natco had received approval from the US FDA earlier. Lupin’s Imatinib Mesylate Tablet, 100 mg (base), and 400 mg (base) is the generic version of Novartis’s Gleevec tablets 100mg and 400 mg. Imatinib Mesylate tablet is developed with the aim of the treatment of adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) and many other types of cancer.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global imatinib drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Novartis AG
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Lupin, Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Mylan N.V.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Dr. Reddy’s Laboratories Ltd.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Teva Pharmaceutical Industry, Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Imatinib Drug Market by Drug Form
5.1.1. Tablet
5.1.2. Capsule
5.2. Global Imatinib Drug Market by Application
5.2.1. Blood Cancer (Leukemia and Other Blood Cancers)
5.2.2. Gastrointestinal Stromal Tumors (GIST)
5.2.3. Skin Tumors (Dermatofibrosarcoma Protuberans)
5.2.4. Other Tumors (Systemic Mastocytosis)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Apotex Inc.
7.2. Cipla, Inc.
7.3. Dr. Reddy’s Laboratory, Ltd.
7.4. Glenmark Pharmaceutical, Ltd.
7.5. Lupin, Ltd.
7.6. Mylan N.V.
7.7. Novartis AG
7.8. Sun Pharmaceutical Industries, Ltd.
7.9. Teva Pharmaceutical Industry, Ltd.
1. GLOBAL IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY DRUG FORM, 2019-2026 ($ MILLION)
2. GLOBAL TABLET MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL CAPSULE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
5. GLOBAL Blood Cancer MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL GASTROINTESTINAL STROMAL TUMORS (GIST) MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL SKIN TUMORS (DERMATOFIBROSARCOMA PROTUBERANS) MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
8. GLOBAL OTHER TUMORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
10. NORTH AMERICAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. NORTH AMERICAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2019-2026 ($ MILLION)
12. NORTH AMERICAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
13. EUROPEAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
14. EUROPEAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY DRUG FORM, 2019-2026 ($ MILLION)
15. EUROPEAN IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
16. ASIA-PACIFIC IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
17. ASIA-PACIFIC IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY DRUG FORM, 2019-2026 ($ MILLION)
18. ASIA-PACIFIC IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
19. REST OF THE WORLD IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY DRUG FORM, 2019-2026 ($ MILLION)
20. REST OF THE WORLD IMATINIB DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. GLOBAL IMATINIB DRUG MARKET SHARE BY DRUG FORM, 2019 VS 2026 (%)
2. GLOBAL IMATINIB DRUG MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
3. GLOBAL IMATINIB DRUG MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. US IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
6. UK IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD IMATINIB DRUG MARKET SIZE, 2019-2026 ($ MILLION)
